Dr. Lesser on Armodafinil for Radiation-Induced Fatigue

Glenn J. Lesser, MD
Published: Thursday, Aug 01, 2013

Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for radiation-induced fatigue in patients with brain tumors.

Fortunately, Lesser says, researchers were able to look at a variety of endpoints in the phase II double-blind placebo-controlled study. Sleepiness, time spent sleeping, and other quality of life metrics standardized in the field were analyzed.

In the study, the group as a whole did not seem to benefit from armodafinil. However, the half of the population with lower initial quality of life scores did see a marked, statistically significant benefit when armodafinil was added to radiation therapy.

Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for radiation-induced fatigue in patients with brain tumors.

Fortunately, Lesser says, researchers were able to look at a variety of endpoints in the phase II double-blind placebo-controlled study. Sleepiness, time spent sleeping, and other quality of life metrics standardized in the field were analyzed.

In the study, the group as a whole did not seem to benefit from armodafinil. However, the half of the population with lower initial quality of life scores did see a marked, statistically significant benefit when armodafinil was added to radiation therapy.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x